Wellington Management Ups Merck Stake, Reduces Pfizer Q3 Stock Holding

Wall St. Watchdog reveals information regarding Wellington Management’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 238 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $38.368 billion.

  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011 reported holding 112,489,651 shares with a market value of $3,969,759,887. This comprised 1.43% of the total portfolio. On 09/30/2011 reported holding 116,041,053 shares with a market value of $3,794,542,522. This comprised 1.65% of the total portfolio. The net change in shares for this position over the two quarters is 3,551,402. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011 reported holding 184,422,994 shares with a market value of $3,799,113,747. This comprised 1.36% of the total portfolio. On 09/30/2011 reported holding 183,075,746 shares with a market value of $3,236,779,245. This comprised 1.41% of the total portfolio. The net change in shares for this position over the two quarters is -1,347,248. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011 reported holding 62,115,215 shares with a market value of $3,203,902,903. This comprised 1.15% of the total portfolio. On 09/30/2011 reported holding 62,221,466 shares with a market value of $2,869,653,945. This comprised 1.25% of the total portfolio. The net change in shares for this position over the two quarters is 106,251. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011 reported holding 32,479,176 shares with a market value of $2,160,514,678. This comprised 0.78% of the total portfolio. On 09/30/2011 reported holding 34,506,260 shares with a market value of $2,197,703,652. This comprised 0.96% of the total portfolio. The net change in shares for this position over the two quarters is 2,027,084. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011 reported holding 50,568,324 shares with a market value of $1,897,829,138. This comprised 0.68% of the total portfolio. On 09/30/2011 reported holding 52,835,740 shares with a market value of $1,953,337,372. This comprised 0.85% of the total portfolio. The net change in shares for this position over the two quarters is 2,267,416. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011 reported holding 30,264,051 shares with a market value of $1,765,907,330. This comprised 0.63% of the total portfolio. On 09/30/2011 reported holding 30,797,114 shares with a market value of $1,692,609,357. This comprised 0.74% of the total portfolio. The net change in shares for this position over the two quarters is 533,063. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011 reported holding 47,173,179 shares with a market value of $1,817,582,529. This comprised 0.65% of the total portfolio. On 09/30/2011 reported holding 50,691,886 shares with a market value of $1,684,998,376. This comprised 0.73% of the total portfolio. The net change in shares for this position over the two quarters is 3,518,707. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011 reported holding 38,011,870 shares with a market value of $1,832,932,418. This comprised 0.66% of the total portfolio. On 09/30/2011 reported holding 40,540,399 shares with a market value of $1,508,913,700. This comprised 0.66% of the total portfolio. The net change in shares for this position over the two quarters is 2,528,529. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011 reported holding 33,630,787 shares with a market value of $973,947,561. This comprised 0.35% of the total portfolio. On 09/30/2011 reported holding 37,334,669 shares with a market value of $1,171,561,882. This comprised 0.51% of the total portfolio. The net change in shares for this position over the two quarters is 3,703,882. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Forest Laboratories Inc. (NYSE:FRX): On 06/30/2011 reported holding 34,266,195 shares with a market value of $1,348,032,117. This comprised 0.48% of the total portfolio. On 09/30/2011 reported holding 34,332,266 shares with a market value of $1,057,090,502. This comprised 0.46% of the total portfolio. The net change in shares for this position over the two quarters is 66,071. About Company: Forest Laboratories, Inc. develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses. Forest’s products are marketed in the United States and eastern Europe.

(Note: Data regarding Wellington Management’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>